GLP-1 Weight-Loss Drugs in India: How They Work and Why Medical Supervision is Essential

ଆନ୍ତର୍ଜାତୀୟ

ତେଲ ଦର $100 ଉର୍ଦ୍ଧ୍ୱରେ: ହର୍ମୁଜ୍ ସଙ୍କଟରେ ବିଶ୍ୱ ଉର୍ଜା...

April 13, 2026

‘ୟୁନିଫର୍ମ ଡିପ୍ଲୋମେସି’ରେ ପାକିସ୍ତାନର ଶକ୍ତିକେନ୍ଦ୍ର: ମୁନିରଙ୍କ ପୋଷାକ ପରିବର୍ତ୍ତନରେ ରାଜନୈତିକ...

April 11, 2026

ଆର୍ଟେମିସ୍–II ମିଶନ୍ ସଫଳ: ଚନ୍ଦ୍ର ପରିକ୍ରମା ପରେ ସୁରକ୍ଷିତ ଫେରିଲେ...

April 11, 2026

ଇରାନରେ ଭୟାବହ ମୁଦ୍ରାସ୍ଫୀତି: ଅଣ୍ଡା ୧.୨୫ ଲକ୍ଷ, କ୍ଷୀର ଲିଟରକୁ...

April 11, 2026

ଶିକ୍ଷା

World Bank ଚେତାବନୀ: ମଧ୍ୟପ୍ରାଚ୍ୟ ଯୁଦ୍ଧ ଦ୍ୱାରା ବିଶ୍ୱ ବୃଦ୍ଧି...

April 11, 2026

Central Board of Secondary Educationର 3-ଭାଷା ନୀତି: 3ଟି...

April 11, 2026

Word of the day: What 'Laconic' means and...

April 11, 2026

Elon Muskଙ୍କ ଆଜିର ଉଦ୍ଧୃତି: ବିଫଳତା ମଧ୍ୟ ଏକ ବିକଳ୍ପ

April 11, 2026

GLP-1 Weight-Loss Drugs in India: How They Work and Why Medical Supervision is Essential

GLP-1 drugs like Mounjaro, Wegovy, and Ozempic are transforming obesity treatment in India, helping patients achieve significant weight loss. Experts stress these are powerful metabolic medications that require careful medical supervision to ensure safety and effectiveness.

Published by Somesh | February 11, 2026

GLP-1 drugs, including Mounjaro, Wegovy, and Ozempic, have become increasingly popular in India for their ability to promote significant weight loss. Originally developed to treat type 2 diabetes, these medications mimic gut hormones that regulate appetite and blood sugar, helping patients reduce hunger, slow digestion, and lose weight effectively over months. Their use has expanded beyond diabetes care to include obesity-related conditions like PCOS and fertility challenges.

Stand-up comedian Aishwarya Mohanraj recently shared her experience of losing 22 kg in six months using these drugs, highlighting their potential impact. However, the high cost—up to Rs 13,125 per month for Mounjaro—remains a barrier for long-term use.

Experts such as Dr Anoop Misra, Dr Ambrish Mithal, and Dr V Mohan emphasise that GLP-1 therapy is not a cosmetic shortcut but a medical intervention. Candidates are usually adults with a BMI of 30 or above, or 27 and above with comorbidities, after thorough metabolic evaluation. Screening for gallbladder health, liver function, pregnancy, and body composition is crucial before starting therapy.

Medical supervision ensures proper dosage, gradual titration, and safe discontinuation to minimise side effects and the risk of rebound weight gain. While GLP-1 drugs can be transformative, self-prescription or abrupt stopping can be dangerous. The key takeaway: these medications are powerful tools for metabolic health but must be used responsibly under the guidance of qualified healthcare professionals.